cagrilintide with semaglutide New in the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide– for Overweight and Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ Co-formulation of Semaglutide and Cagrilintide

When researching the best ways to combat oxidative stress, two names frequently appear together: glutathione and N-acetylcysteine, or NAC

Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity

Ipamorelin's human data is limited to two published pharmacokinetic/pharmacodynamic studies: a 1999 PK/PD study (PMID: 10496658) that documented dose-response relationships and peak GH at 30-40 minutes post-injection in human volunteers, and a completed Phase II clinical trial for postoperative ileus (NCT00672074), after which ipamorelin's development for this indication was discontinued without approval

Association of maternal weight gain in pregnancy with offspring obesity and metabolic and vascular traits in childhood

GLP-1 agonists for other SUDs Opioids Preclinical studies of GLP-1 receptor agonists for opioid use disorder (OUD) have shown some promise, particularly liraglutide (Douton JE et al, Addict Biol 2022;27(2):e13117)